PPG developed a comprehensive IP strategy to secure exclusivity, shepherding this promising startup through a series of rapidly evolving steps.
Launched through the health sciences VC PureTech Health, Alivio Therapeutics is pioneering a new way to treat inflammatory diseases based on precise tuning of the immune system at the site of disease. PPG developed a comprehensive IP strategy to secure exclusivity, shepherding this promising startup through a series of rapidly evolving steps.
Alivio began its journey by licensing technology from Partners Healthcare Innovation. PPG drafted, filed and prosecuted patent applications in both the US and numerous foreign jurisdictions on behalf of both parties. Four platform technology patents have been secured to date, which are sufficiently broad to allow the science and potential resulting products to continue to develop. We continue to prosecute pending applications and draft new ones to further protect and grow Alivio’s expanding portfolio.
Most recently, Alivio entered into a partnership with Purdue Pharma LP and secured funding via the U.S. Department of Defense Technology/Therapeutic Development Award to support Alivio’s preclinical research and development activities. This will enable the eventual filing of an investigational new drug application. The company is well-positioned to attract further investment and potential partnerships in the future.
